awmsg logo



levonorgestrel (Jaydess®)


Reference No. 1158

Publication date:
16/07/2015


Appraisal information

levonorgestrel (Jaydess®) 13.5 mg intrauterine device


Company: Bayer Healthcare Pharmaceuticals
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 13/05/2015
AWMSG meeting date: 17/06/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1515
Ministerial ratification: 15/07/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Levonorgestrel (Jaydess®) is recommended as an option for use within NHS Wales for contraception for up to three years.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download